Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Monali Desai"'
Autor:
John F. Seymour, Peter Hillmen, Monali Desai, Elisa Cerri, Maria E. Verdugo, Andrea Best, Todd Busman, Jalaja Potluri, Su Young Kim, John F. Gerecitano, Jeffrey A. Jones, Stephan Stilgenbauer, Andrew W. Roberts, William Wierda, Michael Hallek, Matthew S. Davids
Purpose: The oral BCL-2 inhibitor venetoclax is an effective therapy for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), including disease with high-risk genomic features such as chromosome 17p deletion [del(17p)] or progr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a357ba7adc893e346748e02d439c733
https://doi.org/10.1158/1078-0432.c.6527589
https://doi.org/10.1158/1078-0432.c.6527589
Autor:
John F. Seymour, Peter Hillmen, Monali Desai, Elisa Cerri, Maria E. Verdugo, Andrea Best, Todd Busman, Jalaja Potluri, Su Young Kim, John F. Gerecitano, Jeffrey A. Jones, Stephan Stilgenbauer, Andrew W. Roberts, William Wierda, Michael Hallek, Matthew S. Davids
Supplementary Data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d0363c4436c4ec518bca6e926abe482
https://doi.org/10.1158/1078-0432.22470501.v1
https://doi.org/10.1158/1078-0432.22470501.v1
Autor:
Thomas Herzog, John Hays, Kathleen Moore, Panagiotis Konstantinopoulos, Lucy Gilbert, Bradley Monk, David O’Malley, Joyce Barlin, Jessicca Rege, Monali Desai, Yangchun Du, Rita Dalal, Robert L Coleman, Jalid Sehouli
Publikováno v:
E-Posters (Trials In Progress).
Autor:
Thomas J Herzog, Kathleen Moore, Panagiotis A Konstantinopoulos, Lucy Gilbert, John L Hays, Bradley J Monk, David M O’Malley, Joyce N Barlin, Julie R Graham, Monali Desai, Yan Wang, Yangchun Du, Rita Dalal, Robert L Coleman, Jalid Sehouli
Publikováno v:
Ovarian cancer.
Autor:
Michael Steel, Chantal El-Haddad, Linda Härmark, Monali Desai, Ulrika Nörby, Sashka Hristoskova, Benedikte Noël-Cuppers, Ludivine Douarin
Publikováno v:
Expert Opinion on Drug Safety
Background: Inconsistencies in information on safety of medicine use during pregnancy and lactation can result in sub-optimal treatment for pregnant and lactating women, risks to the fetus or child...
Autor:
Thomas Herzog, Kathleen Moore, Panagiotis Konstantinopoulos, Lucy Gilbert, John Hays, Bradley Monk, David O’Malley, Jalid Sehouli, Julie Graham, Monali Desai, Yan Wang, Yangchun Du, Lei Sun, Rita Dalal, Robert Coleman
Publikováno v:
Gynecologic Oncology. 166:S169
Autor:
Thomas J. Herzog, Kathleen N. Moore, Panagiotis A. Konstantinopoulos, Lucy Gilbert, John L. Hays, Bradley J. Monk, David M. O'Malley, Jalid Sehouli, Joyce N. Barlin, Julie R. Graham, Monali Desai, MD, Yan Wang, Yangchun Du, Rita P. Dalal, Robert L. Coleman
Publikováno v:
Journal of Clinical Oncology. 40:TPS5609-TPS5609
TPS5609 Background: ARTISTRY-7 will evaluate the novel engineered cytokine nemvaleukin alfa (nemvaleukin, ALKS 4230) in pts with gynecologic cancers. Epithelial ovarian cancer (OC) is the 7th most common cause of cancer mortality in women. OC is an a
Autor:
Sarina Anne Piha-Paul, Corrine F. Elliott, Yangchun Du, Julie R. Graham, Monali Desai, MD, Yan Wang, Rita P. Dalal, Nehal J. Lakhani
Publikováno v:
Journal of Clinical Oncology. 40:TPS2684-TPS2684
TPS2684 Background: Nemvaleukin alfa (nemvaleukin, ALKS 4230) is a novel engineered cytokine that selectively binds the intermediate-affinity interleukin-2 (IL-2) receptor, preferentially activating and expanding antitumor CD8+ T cells and NK effecto
Autor:
Emiliano Calvo, Valentina Boni, Arvind Chaudhry, Philip R. Debruyne, Seth D Rosen, Yan Wang, Lei Sun, Monali Desai, MD, Rita P. Dalal, Yangchun Du, Julie R. Graham, Piotr Tomczak, MD
Publikováno v:
Journal of Clinical Oncology. 40:330-330
330 Background: Nemvaleukin alfa (nemvaleukin, ALKS 4230) is a novel engineered cytokine that selectively binds to the intermediate-affinity IL-2 receptor, preferentially activating and expanding antitumor CD8+ T and NK cells, with minimal expansion
Autor:
Sebastian Böttcher, Ahmed Salem, Su Young Kim, Stephan Stilgenbauer, Matthew S. Davids, Michael Hallek, Stephen P. Mulligan, Sarit Assouline, Clemens-Martin Wendtner, John F. Seymour, Peter Hillmen, Brenda Chyla, Jennifer Arzt, Johannes Bloehdorn, Lang Zhou, Gary S. Gordon, Johannes Schetelig, Andrew W. Roberts, Anna Schuh, Wojciech Jurczak, Steven Coutre, Talha Munir, Maria Verdugo, Monali Desai, Barbara Eichhorst, William G. Wierda
Publikováno v:
Journal of Clinical Oncology. 36:1973-1980
Purpose Venetoclax is an orally bioavailable B-cell lymphoma 2 inhibitor. US Food and Drug Administration and European Medicines Agency approval for patients with 17p deleted relapsed/refractory chronic lymphocytic leukemia [del(17p) CLL] was based o